ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer.
Matthew P Goetz, Seth A Wander, Thomas Bachelot...
https://pubmed.ncbi.nlm.nih.gov/40222048/Actively Recruiting
Led by LeonaBio · Updated on 2026-10-29
600
Participants Needed
224
Research Sites
52 weeks
Total Duration
Researchers are evaluating the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for treating pre- and postmenopausal women and men with locally advanced or metastatic estrogen receptor positive ERhuman epidermal growth factor 2 negative HER2- breast cancer that has an ESR1 mutation. This study focuses on patients who have previously received ribociclib or palbociclib-based treatment and aims to compare the effectiveness, safety, and tolerability of these two treatment combinations. Participants will receive either 5 mg per day of oral lasofoxifene plus oral abemaciclib 150 mg twice daily, or fulvestrant 500 mg given intramuscularly on Days 1, 15, and 29, then once monthly thereafter, combined with oral abemaciclib 150 mg twice daily. The study is randomized and open-label, allowing comparison between these two treatment combinations over time. During the study, participants will be closely monitored for progression-free survival, objective response rate, overall survival, clinical benefit rate, duration and time to response, time to cytotoxic chemotherapy, quality of life using a specific breast cancer assessment tool, and the incidence of adverse events. The study includes various assessments and safety monitoring over approximately three years to evaluate these outcomes and the participants response to the treatments.
CONDITIONS
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
S
Simon Daggett - Senior Vice President, Clinical Operations
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
LeonaBio
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Lasofoxifene (oral) + abemaciclib (oral) | Fulvestrant (intramuscular) + abemaciclib (oral) |
|---|---|---|
| What it is | Combination of oral lasofoxifene (selective estrogen receptor modulator) and oral abemaciclib (CDK4/6 inhibitor). | Combination of intramuscular fulvestrant (selective estrogen receptor degrader) and oral abemaciclib (CDK4/6 inhibitor). |
| Role in the trial | Investigational study arm evaluating a new endocrine therapy with a CDK4/6 inhibitor. | Active comparator arm using established second-line hormonal therapy with a CDK4/6 inhibitor. |
| Primary use | To treat advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation after progression on an aromatase inhibitor plus CDK4/6 inhibitor. | To treat advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation after progression on an aromatase inhibitor plus CDK4/6 inhibitor. |
| How it is given or performed | Lasofoxifene is taken orally once daily, and abemaciclib is taken orally twice daily. | Fulvestrant is given as an intramuscular injection on specified days, with abemaciclib given orally twice daily. |
| Evidence status | Efficacy and safety for this combination are under investigation; no mature results for progression-free survival or overall survival are posted. | Fulvestrant plus abemaciclib is an established combination with clinical evidence supporting its use in this patient population. |
| Important limitations | Long-term effectiveness, impact on survival, and safety profile compared to standard treatments are not yet known. | Guideline recommendations for sequencing endocrine therapy after AI plus CDK4/6 inhibition vary; optimal strategies for ESR1-mutant disease are still under study. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Up to approximately 3 years
Participants receive either lasofoxifene plus abemaciclib or fulvestrant plus abemaciclib as prescribed in the study.
Regular visits for treatment administration and monitoring
Duration - Up to approximately 3 years
Participants are monitored for treatment effects, disease progression, quality of life, and adverse events throughout and after treatment.
Periodic assessments and safety monitoring visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Matthew P Goetz, Seth A Wander, Thomas Bachelot...
https://pubmed.ncbi.nlm.nih.gov/40222048/LeonaBio
Lead Sponsor